Ispire Technology Inc (ISPR)

Reports for Ispire Technology Inc

Ispire Technology Inc
ISPR
28-09-2025
Read Report
Ispire Technology Inc
ISPR
18-07-2025
Read Report

Industries

Tobacco
110008002
View Industry

Analysis

No analyses available for Ispire Technology Inc yet.

Latest News about Ispire Technology Inc

FPOST
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based...
1749425905 | FPOST
INVESTING
CRISPR Therapeutics' SWOT analysis: gene-editing pioneer's stock faces pivotal year
1748140030 | INVESTING
INVESTING
Scribe Therapeutics to Highlight In Vivo CRISPR-based Genome Editing Data for Duchenne Muscular...
1746450725 | INVESTING
SALPHA
CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts
1746434696 | SALPHA
NASDAQ
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
1744357500 | NASDAQ
NASDAQ
Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why
1740787200 | NASDAQ
FPOST
Bahrain Makes History with First Successful CRISPR-Based Sickle Cell Treatment Outside the US
1739707856 | FPOST
NASDAQ
April 4th Options Now Available For CRISPR Therapeutics (CRSP)
1739466041 | NASDAQ
NASDAQ
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
1739403420 | NASDAQ
NASDAQ
March 28th Options Now Available For CRISPR Therapeutics (CRSP)
1738866683 | NASDAQ
AG NEWS
Morocco explores CRISPR gene editing to boost agricultural resilience in North Africa
1738774659 | AG NEWS
NASDAQ
CRISPR Therapeutics Enters Oversold Territory (CRSP)
1735335191 | NASDAQ
NASDAQ
1 big new Green Flag for CRISPR Therapeutics' Stock
1734705000 | NASDAQ
Yahoo
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
1734187500 | Yahoo
NASDAQ
3 Things You Need to Know if You Buy CRISPR Therapeutics Today
1734187500 | NASDAQ
INVESTING
CRISPR Therapeutics stock hits 52-week low at $43.37
1734105329 | INVESTING
INVESTING
Editas shifts focus to in vivo CRISPR gene editing
1734037508 | INVESTING
AG NEWS
Vivlion® launches fixed-pair Alexandria, a genome-wide PRCISR™ CRISPR library with unmatched...
1733929200 | AG NEWS
BANKING
Vivlion® launches fixed-pair Alexandria, a genome-wide PRCISR™ CRISPR library with unmatched...
1733929200 | BANKING
AG NEWS
Tres Ejemplos Radicalmente Diferentes de Cómo CRISPR Transformará la Agricultura
1733928738 | AG NEWS
NASDAQ
January 2025 Options Now Available For CRISPR Therapeutics (CRSP)
1733413874 | NASDAQ
SALPHA
CRISPR Therapeutics: Strong Balance Sheet Supports Ambitious Plans Amid Slow Growth
1733213479 | SALPHA
NASDAQ
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?
1732445220 | NASDAQ
INVESTING
Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran...
1731770405 | INVESTING
NASDAQ
First Week of July 2025 Options Trading For CRISPR Therapeutics (CRSP)
1731691048 | NASDAQ
NASDAQ
Where Will CRISPR Therapeutics Be in 3 Years?
1731667500 | NASDAQ
NASDAQ
Ispire Technology Inc. (ISPR) Reports Q1 Loss, Lags Revenue Estimates
1731330603 | NASDAQ
INVESTING
Cathie Wood's ARK trades Trade Desk and CRISPR stock, sells Unity
1731114186 | INVESTING
FPOST
ERS Genomics and Université de Montréal Sign CRISPR/Cas9 License Agreement
1727774840 | FPOST
AG NEWS
MyFloraDNA Launches Crowdfunding Campaign to Combat Peanut Allergies with CRISPR Technology
1721422892 | AG NEWS
Yahoo
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
1721117700 | Yahoo
INVESTING
Intellia reports breakthrough in CRISPR redosing efficacy
1719344253 | INVESTING
Yahoo
CRISPR Therapeutics Stock (NASDAQ:CRSP): Will It Take Off Anytime Soon?
1718822810 | Yahoo
INVESTING
Cathie Wood's ARK buys PagerDuty, CRISPR, sells Zoom stock
1717201708 | INVESTING
INVESTING
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
1716986164 | INVESTING
Yahoo
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
1716729300 | Yahoo
MTLYFOOL
Is CRISPR Therapeutics a Millionaire Maker?
1716383400 | MTLYFOOL
Yahoo
Is CRISPR Therapeutics a Millionaire Maker?
1716383400 | Yahoo
MTLYFOOL
Is CRISPR Therapeutics Stock a Buy?
1715952600 | MTLYFOOL
MTLYFOOL
Is CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.
1715785860 | MTLYFOOL
INVESTING
Pro Research: Wall Street dives into CRISPR Therapeutics' gene editing future
1715687695 | INVESTING
INVESTING
CRISPR Therapeutics shares target cut by Oppenheimer amid rising operating expenses
1715333076 | INVESTING
INVESTING
Baird raises CRISPR Therapeutics shares target as its pipeline progresses
1715264065 | INVESTING
INVESTING
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
1715208245 | INVESTING
SALPHA
Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
1714497904 | SALPHA